The US FDA is to hold a public hearing on 31st May on the safety of products containing cannabis or cannabis-derived compounds ― and stakeholders will be looking for a dividing line
...
Are you already a subscriber? login here
Are you already a subscriber? login here
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.